Sensorion nabs rare pediatric designation for gene therapy; Avalo sells off remaining drug rights for $5M
A French biotech is moving forward on its hearing loss gene therapy, and the FDA is giving the candidate a regulatory boost.
Sensorion put out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
